MedTrace Logo

Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over

NCT00170768 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2008-01-23

No results posted yet for this study

Summary

The purpose of this study is to explore the possible cognitive effects of darifenacin modified release and long-acting oxybutynin.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Darifenacin

Darifenacin modified release 7,5 mg tablets once daily titrated to 15 mg once daily

DRUG

Oxybutynin

Oxybutynin extended release 10 mg tablet once daily titrated to 15 mg, then to 20 mg once daily

DRUG

Placebo

Placebo once daily tablet (sham titration)

Sponsors & Collaborators

Principal Investigators

  • Novartis · East Hanover NJ

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Completion
2005-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00170768 on ClinicalTrials.gov